5.80Open5.80Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover410.06%IV-14.86%PremiumAug 16, 2024Expiry Date6.02Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8324Delta0.1659Gamma0.24Leverage Ratio-0.0072Theta-0.0029Rho-0.20Eff Leverage0.0010Vega
ATAI Life Sciences Stock Discussion
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
You should check out $ATAI Life Sciences(ATAI.US)$ as well. 😉
$ATAI Life Sciences(ATAI.US)$ looks good too! It'll be interesting to see the advancements coming with their medicine. Especially with John Hopkins University doing similar research.
$ATAI Life Sciences(ATAI.US)$ looks good too! It'll be interesting to see the advancements coming with their medicine. Especially with John Hopkins University doing similar research.
$ATAI Life Sciences(ATAI.US)$ looks pretty good too!
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
• ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hour...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
No comment yet